Свистушкин Валерий Михайловичд.м.н., профессор, завкафедрой болезней уха, горла и носа Федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет); тел.:

The most common cause of patients referring to primary care physicians are respiratory diseases. Anatomical and physiological features of the human respiratory system and the type of etiotropic agent determine the characteristic features of the pathogenesis of respiratory pathology. The possibility of self-purification of the respiratory tract is of significant clinical importance - mucociliary clearance, but during the course of respiratory inflammatory diseases, the effectiveness of such purification suffers significantly due to the formation of edema and the increased production of a secretion more dense than the physiological norm provides. Almost all diseases of the upper and lower respiratory tract are accompanied by violations of the composition and rheological properties of the secretion and difficulties in its evacuation. The use of mucoactive drugs in the treatment of patients with inflammatory pathology of the respiratory tract has a tangible economic and clinical effect, reducing the duration of the disease, the need for systemic antibiotic therapy, the frequency and severity of relapses, a positive effect on the number of complications and quality of life. The drug Elmultsin® (erdosteinе), produced by the Russian pharmaceutical company «Obolenskoye», is a representative of a group of secretolytics and respiratory motor function stimulants, is promising for use in the treatment of patients with respiratory diseases accompanied by the formation of viscous sputum, including in conditions of adverse environmental conditions.

Pharyngalgia is one of the most common complaints in both children and adults seeking medical advice. The causes of throat discomfort and pain vary and are explained by anatomo-physiological characteristics of pharynx. The lesion of pharyngeal mucosa and mucosal associated lymphoid tissue develops in 80% of acute respiratory disease cases. Detailed history taking and additional tests are required to confirm the etiology of pharyngalgia that is not related to respiratory infection and to provide appropriate treatment for the patient. Fixed topical combination with complex effectiveness established itself as a leading choice of inflammatory pharynx diseases treatment. Such treatment has the following advantages: the precise point of drug effect, minimal amount of side effects or its complete absence and risk reduction of general micro biome affection. The treatment should also be able to reach hard-to-reach areas and have good sensory properties. The purpose of topical treatment in patients with pharyngeal pathology is to relieve pain quickly, to reduce the inflammation and to prevent secondary infection of mucosa. The drug containing tyrothricin as antibiotic, benzocaine as antiseptic provides antibacterial and benzalkonium chloride as antiseptic, antiviral and analgetic effects. Not only do the early diagnosis and treatment meet the need of the patient to relieve the symptoms quickly but also have a positive impact on disease course and prevent the development of complications.